(Q37917105)

25 August 2017

1 reference

title

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer (English)

1 reference

25 August 2017

1 reference

2

Brogden RN

1 reference

25 August 2017

Henwood JM

1

1 reference

25 August 2017

1 March 1990

1 reference

25 August 2017

1 reference

25 August 2017

39

1 reference

25 August 2017

438-490

1 reference

25 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199039030-00008

25 August 2017

0 references

cites work

New combination chemotherapy for relapsed acute myeloid leukaemia

1 reference

12 December 2020

Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias

1 reference

12 December 2020

Phase II study of etoposide in the treatment of esophageal carcinoma

1 reference

12 December 2020

Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse

1 reference

12 December 2020

Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

1 reference

12 December 2020

Improvement of long-term survival in extensive small-cell lung cancer.

1 reference

12 December 2020

Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

1 reference

12 December 2020

Possible enhancement of vincristine neuropathy by VP-16

1 reference

12 December 2020

Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience

1 reference

12 December 2020

Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer

1 reference

12 December 2020

Chemotherapy of Advanced Non-Small-Cell Lung Cancer with Cyclophosphamide, Adriamycin, Methotrexate, and Procarbazine versus Cisplatin and Etoposide A Randomized Study

1 reference

12 December 2020

High-dose etoposide in the treatment of relapsed primary brain tumors.

1 reference

12 December 2020

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer

1 reference

12 December 2020

Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer

1 reference

12 December 2020

A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer

1 reference

12 December 2020

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

12 December 2020

Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies

1 reference

12 December 2020

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours

1 reference

12 December 2020

Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer

1 reference

12 December 2020

Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma

1 reference

12 December 2020

Etoposide salvage therapy for refractory germ cell tumors: an update

1 reference

12 December 2020

Inefficacy of cisplatin and etoposide as salvage therapy for children with recurrent or unresponsive soft tissue sarcoma.

1 reference

12 December 2020

Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer

1 reference

12 December 2020

Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow

1 reference

12 December 2020

Chemotherapy of refractory germ cell cancer with Etoposide

1 reference

12 December 2020

In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma

1 reference

12 December 2020

Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.

1 reference

12 December 2020

Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma

1 reference

12 December 2020

Variable bioavailability following repeated oral doses of etoposide

1 reference

12 December 2020

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1 reference

12 December 2020

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213

1 reference

12 December 2020

Treatment of persistent or relapsing advanced germ cell neoplasms with cisplatin, etoposide and bleomycin

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

1 reference

12 December 2020

Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

1 reference

12 December 2020

Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.

1 reference

12 December 2020

Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

1 reference

12 December 2020

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus

1 reference

12 December 2020

VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association

1 reference

12 December 2020

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1 reference

12 December 2020

Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns

1 reference

12 December 2020

Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action

1 reference

12 December 2020

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.

1 reference

12 December 2020

High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia

1 reference

12 December 2020

Primary oral etoposide therapy in gestational trophoblastic disease. An update.

1 reference

12 December 2020

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

1 reference

12 December 2020

VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK)

1 reference

12 December 2020

High-dose cisplatin and etoposide in advanced malignancies of childhood

1 reference

12 December 2020

Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium)

1 reference

12 December 2020

Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolit

1 reference

12 December 2020

Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.

1 reference

12 December 2020

Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy

1 reference

12 December 2020

VP-16–213 and cisplatin in the treatment of patients with refractory germ cell tumors

1 reference

12 December 2020

Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

12 December 2020

VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma

1 reference

12 December 2020

Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target

1 reference

12 December 2020

Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen

1 reference

12 December 2020

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

1 reference

12 December 2020

Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines

1 reference

12 December 2020

Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.

1 reference

12 December 2020

Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma

1 reference

12 December 2020

Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage

1 reference

12 December 2020

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1 reference

12 December 2020

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

1 reference

12 December 2020

High dose etoposide does not cause peripheral neuropathy

1 reference

12 December 2020

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party

1 reference

12 December 2020

Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.

1 reference

12 December 2020

Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.

1 reference

12 December 2020

Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma

1 reference

12 December 2020

VP-16 plus cyclophosphamide in the treatment of advanced lung cancer

1 reference

12 December 2020

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study

1 reference

12 December 2020

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

Phase II study of etoposide for carcinoma of the prostate

1 reference

12 December 2020

Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.

1 reference

12 December 2020

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

12 December 2020

High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse

1 reference

12 December 2020

Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.

1 reference

12 December 2020

Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group

1 reference

12 December 2020

Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract

1 reference

12 December 2020

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide

1 reference

12 December 2020

Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors

1 reference

12 December 2020

Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood

1 reference

12 December 2020

Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.

1 reference

12 December 2020

Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer

1 reference

12 December 2020

Action of etoposide (VP-16-123) on human cells: no evidence for topoisomerase II involvement in excision repair of u.v.-induced DNA damage, nor for mitochondrial hypersensitivity in ataxia telangiectasia

1 reference

12 December 2020

Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.

1 reference

12 December 2020

Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer

1 reference

12 December 2020

Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

A comparison of the mechanisms of action of VP-16-213 and podophyllotoxin

1 reference

12 December 2020

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors

1 reference

12 December 2020

Cis-dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non-small cell lung cancer

1 reference

12 December 2020

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

1 reference

12 December 2020

Antimetastasis effect of two derivatives of epiposophyllotoxin in mice

1 reference

12 December 2020

Possible benefit of doxorubicin treatment in patients with refractory germ cell cancer

1 reference

12 December 2020

CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study

1 reference

12 December 2020

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer

1 reference

12 December 2020

Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine

1 reference

12 December 2020

Phase II study of etoposide in previously untreated squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents

1 reference

12 December 2020

Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung.

1 reference

12 December 2020

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

1 reference

12 December 2020

The podophyllotoxin derivatives VP16-213 and VM26.

1 reference

12 December 2020

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study

1 reference

12 December 2020

Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients

1 reference

12 December 2020

VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms

1 reference

12 December 2020

Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung

1 reference

12 December 2020

Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

1 reference

12 December 2020

Intracarotid VP-16 in malignant brain tumors.

1 reference

12 December 2020

Treatment of chronic myelomonocytic leukemia with low dose etoposide

1 reference

12 December 2020

Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines

1 reference

12 December 2020

Improved prognosis for children with stage IV neuroblastoma: high-dose melphalan and autologous unpurged marrow transplantation after aggressive surgery and short chemotherapy with cisplatinum and etoposide

1 reference

12 December 2020

Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide

1 reference

12 December 2020

VP-16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report

1 reference

12 December 2020

Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer

1 reference

12 December 2020

Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues.

1 reference

12 December 2020

Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.

1 reference

12 December 2020

Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow

1 reference

12 December 2020

Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapy: in vitro and in vivo studies

1 reference

12 December 2020

Etoposide (VP-16-213)

1 reference

12 December 2020

Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts.

1 reference

12 December 2020

Management of high risk patients with advanced testis cancer: National Cancer Institute approach

1 reference

12 December 2020

Etoposide and cisplatin salvage chemotherapy for small cell lung cancer

1 reference

12 December 2020

VP-16 and adriamycin in patients with advanced breast cancer.

1 reference

12 December 2020

The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients

1 reference

12 December 2020

Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial

1 reference

12 December 2020

Cisplatin plus VP16-213 in refractory ovarian carcinoma

1 reference

12 December 2020

Oral etoposide in gestational trophoblastic disease

1 reference

12 December 2020

Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.

1 reference

12 December 2020

The clinical pharmacology of VM26 and VP16-213. A brief overview

1 reference

12 December 2020

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1 reference

12 December 2020

Etoposide single-agent chemotherapy for solid tumors

1 reference

12 December 2020

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

12 December 2020

Analysis and interpretation of response rates for anticancer drugs

1 reference

12 December 2020

Etoposide, cisplatin and doxorubicin in patients with small cell lung cancer: tumor response and long term survival

1 reference

12 December 2020

Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial

1 reference

12 December 2020

Pharmacokinetics of high dose etoposide (VP 16-213)

1 reference

12 December 2020

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

1 reference

12 December 2020

A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs.

1 reference

12 December 2020

Chronic daily administration of oral etoposide--a phase I trial

1 reference

12 December 2020

Effect of oxygen on the cytotoxicity and antitumor activity of etoposide

1 reference

12 December 2020

Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer

1 reference

12 December 2020

Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204

1 reference

12 December 2020

Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer

1 reference

12 December 2020

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1 reference

12 December 2020

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer

1 reference

12 December 2020

Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.

1 reference

12 December 2020

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

1 reference

12 December 2020

VP16-213 as a single agent in advanced testicular tumors

1 reference

12 December 2020

Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

1 reference

12 December 2020

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)

1 reference

12 December 2020

A phase I trial of continuous infusion VP16-213 (etoposide).

1 reference

12 December 2020

VP 16-213 in acute myelogenous leukaemia

1 reference

12 December 2020

Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosyl-cytosine, and etoposide

1 reference

12 December 2020

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

12 December 2020

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

1 reference

12 December 2020

High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung

1 reference

12 December 2020

Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma

1 reference

12 December 2020

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

1 reference

12 December 2020

Lack of potentiation of vincristine-induced neurotoxicity by VP-16–213

1 reference

12 December 2020

Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay

1 reference

12 December 2020

Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia

1 reference

12 December 2020

High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study

1 reference

12 December 2020

Further advances in the management of malignant teratomas of the testis and other sites

1 reference

12 December 2020

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

1 reference

12 December 2020

Interaction of etoposide and cisplatin in an in vitro tumor model

1 reference

12 December 2020

Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

12 December 2020

High-dose etoposide for refractory malignancies: a phase I study

1 reference

12 December 2020

Combination vincristine and VP-16-213: evaluation of drug sequence

1 reference

12 December 2020

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

12 December 2020

A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia

1 reference

12 December 2020

Etoposide: a pharmacokinetic profile including an assessment of bioavailability

1 reference

12 December 2020

Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer.

1 reference

12 December 2020

Pharmacokinetics of etoposide in gestochoriocarcinoma

1 reference

12 December 2020

Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial

1 reference

12 December 2020

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

12 December 2020

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1 reference

12 December 2020

Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

1 reference

12 December 2020

Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide

1 reference

12 December 2020

Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16.

1 reference

12 December 2020

Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies

1 reference

12 December 2020

The pharmacokinetics of high dose cyclophosphamide and high dose etoposide

1 reference

12 December 2020

Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin

1 reference

12 December 2020

EVA treatment for recurrent or unresponsive Hodgkin's disease.

1 reference

12 December 2020

Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin

1 reference

12 December 2020

Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.

1 reference

12 December 2020

Combined modalities of resistance in etoposide-resistant human KB cell lines.

1 reference

12 December 2020

Cisplatin and etoposide: an effective treatment for refractory breast carcinoma.

1 reference

12 December 2020

Chemotherapy of invasive carcinoma of the bladder

1 reference

12 December 2020

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial

1 reference

12 December 2020

Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents

1 reference

12 December 2020

Three months treatment with chemotherapy and radiotherapy for small cell lung cancer

1 reference

12 December 2020

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

1 reference

12 December 2020

VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas

1 reference

12 December 2020

Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation.

1 reference

12 December 2020

Qualitative and quantitative aspects of intercalator-induced DNA strand breaks

1 reference

12 December 2020

Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213

1 reference

12 December 2020

Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas

1 reference

12 December 2020

Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

1 reference

12 December 2020

Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial

1 reference

12 December 2020

Review of etoposide single-agent activity

1 reference

12 December 2020

Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.

1 reference

12 December 2020

Chemotherapy for metastatic non-small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV)

1 reference

12 December 2020

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients

1 reference

12 December 2020

Etoposide, methotrexate, and bleomycin in drug-resistant gestational trophoblastic disease

1 reference

12 December 2020

Phase II trial of VP-16-213 in advanced ovarian carcinoma

1 reference

12 December 2020

Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma

1 reference

12 December 2020

Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia

1 reference

12 December 2020

Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas

1 reference

12 December 2020

Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation

1 reference

12 December 2020

Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma

1 reference

12 December 2020

Cisplatin, etoposide, and radiotherapy in regional inoperable squamous cell carcinoma of the bronchus

1 reference

12 December 2020

Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide

1 reference

12 December 2020

Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells

1 reference

12 December 2020

Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

1 reference

12 December 2020

Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study

1 reference

12 December 2020

Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984).

1 reference

12 December 2020

Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer

1 reference

12 December 2020

Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer

1 reference

12 December 2020

Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy.

1 reference

12 December 2020

Phase II study with etoposide in previously untreated advanced breast cancer

1 reference

12 December 2020

Multicenter Phase II trial of etoposide in refractory small cell lung cancer

1 reference

12 December 2020

Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma

1 reference

12 December 2020

A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules

1 reference

12 December 2020

VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.

1 reference

12 December 2020

VP-16–213 salvage therapy for refractory germinal neoplasms

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

12 December 2020

Phase II clinical trial of VP-16-213 in ovarian cancer

1 reference

12 December 2020

Etoposide-induced DNA cleavage in human leukemia cells

1 reference

12 December 2020

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

12 December 2020

The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.

1 reference

12 December 2020

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

1 reference

12 December 2020

Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma

1 reference

12 December 2020

A phase III of cisplatinum versus cisplatinum-etoposide for previously untreated squamous cell carcinoma of the head and neck

1 reference

12 December 2020

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

12 December 2020

Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors

1 reference

12 December 2020

Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.

1 reference

12 December 2020

Inhibition of DNA ligase from human thymocytes and normal or leukemic lymphocytes by antileukemic drugs

1 reference

12 December 2020

Chemotherapy of advanced non-small cell lung cancer with the use of cis-platinum and VP 16-213

1 reference

12 December 2020

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

1 reference

12 December 2020

Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

1 reference

12 December 2020

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

1 reference

12 December 2020

Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors

1 reference

12 December 2020

Synergistic antitumor activity of vincristine and VP-16-213

1 reference

12 December 2020

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

12 December 2020

Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.

1 reference

12 December 2020

Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer

1 reference

12 December 2020

The effect of dose on the bioavailability of oral etoposide.

1 reference

12 December 2020

Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy

1 reference

12 December 2020

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function

1 reference

12 December 2020

High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.

1 reference

12 December 2020

Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro

1 reference

12 December 2020

Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro

1 reference

12 December 2020

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

12 December 2020

High-dose cis-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity

1 reference

12 December 2020

Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.

1 reference

12 December 2020

Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia

1 reference

12 December 2020

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

1 reference

12 December 2020

Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide

1 reference

12 December 2020

Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma

1 reference

12 December 2020

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer

1 reference

12 December 2020

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Results of MIME salvage regimen for recurrent or refractory lymphoma

1 reference

12 December 2020

Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

1 reference

12 December 2020

Effects of the antitumor drug VP16 (etoposide) on the archaebacterial Halobacterium GRB 1.7 kb plasmid in vivo

1 reference

12 December 2020

Hypersensitivity reactions induced by etoposide

1 reference

12 December 2020

Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.

1 reference

12 December 2020

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique

1 reference

12 December 2020

Etoposide for therapy-resistant testicular tumors.

1 reference

12 December 2020

Phase II study of oral VP-16-213 in small cell lung cancer

1 reference

12 December 2020

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

1 reference

12 December 2020

cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma

1 reference

12 December 2020

Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer

1 reference

12 December 2020

Treatment of acute non lymphocytic leukemia. Results of a prospective trial of daunorubicin, arabinosylcytosine and 6-thioguanine (DAT) versus DAT plus vindesine and etoposide

1 reference

12 December 2020

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts

1 reference

12 December 2020

Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures

1 reference

12 December 2020

Etoposide as single agent and in combination with cis-platinum for malignant lymphomas

1 reference

12 December 2020

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

1 reference

12 December 2020

Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer

1 reference

12 December 2020

Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.

1 reference

12 December 2020

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

1 reference

12 December 2020

High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors

1 reference

12 December 2020

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia

1 reference

12 December 2020

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

1 reference

12 December 2020

DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action

1 reference

12 December 2020

VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study

1 reference

12 December 2020

Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas

1 reference

12 December 2020

Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole

1 reference

12 December 2020

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration

1 reference

12 December 2020

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

1 reference

12 December 2020

Model studies of etoposide resistance.

1 reference

12 December 2020

Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide

1 reference

12 December 2020

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Altered protein binding of etoposide in patients with cancer

1 reference

12 December 2020

A phase II study of oral etoposide in elderly patients with small cell lung cancer

1 reference

12 December 2020

Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.

1 reference

12 December 2020

The effect of etoposide on human CFU-GM.

1 reference

12 December 2020

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

1 reference

12 December 2020

Pharmacokinetics of high-dose etoposide.

1 reference

12 December 2020

Acute vasomotor response--a reaction to etoposide

1 reference

12 December 2020

Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).

1 reference

12 December 2020

Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party

1 reference

12 December 2020

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer

1 reference

12 December 2020

Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy

1 reference

12 December 2020

High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy

1 reference

12 December 2020

The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.

1 reference

12 December 2020

VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer

1 reference

12 December 2020

Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro.

1 reference

12 December 2020

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

12 December 2020

Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group

1 reference

12 December 2020

Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung

1 reference

12 December 2020

Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma

1 reference

12 December 2020

Pharmacokinetics of VP16-213 given by different administration methods

1 reference

12 December 2020

Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC)

1 reference

12 December 2020

Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. A preliminary report.

1 reference

12 December 2020

Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer

1 reference

12 December 2020

Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung

1 reference

12 December 2020

Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease

1 reference

12 December 2020

Etoposide pharmacokinetics in patients with normal and abnormal organ function

1 reference

12 December 2020

Etoposide (VP-16-213). Current status of an active anticancer drug

1 reference

12 December 2020

In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).

1 reference

12 December 2020

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

1 reference

12 December 2020

Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer

1 reference

12 December 2020

Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer

1 reference

12 December 2020

Cyclic alternating chemotherapy for small cell carcinoma of the lung

1 reference

12 December 2020

Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275)

1 reference

12 December 2020

Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen

1 reference

12 December 2020

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

1 reference

12 December 2020

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer

1 reference

12 December 2020

An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer

1 reference

12 December 2020

A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer

1 reference

12 December 2020

10.2165/00003495-199039030-00008

Identifiers

DOI

1 reference

PubMed ID

2184009

Dimensions Publication ID

25 August 2017

0 references

1 reference

PubMed ID

2184009